2 active not recruiting, 2 completed, 2 unknown, 1 not yet recruiting. 8 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 2, Completed 2, Unknown 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow GATA2 Deficiency: new trials by email Literature Review of GATA2 Deficiency trials Research Report on GATA2 Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 64 | 2026-09-15 | 2026-07-22 |
| AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia AB8939, Venetoclax - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | AB Science | 78 | 2022-06-01 | 2025-10-02 |
| Total Lymphoid Irradiation Pre-HSCT in Severe Congenital Neutropenia conditioning with TLI - Severe Congenital Neutropenia, GATA2 Deficiency | Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 10 | 2021-04-14 | 2021-04-14 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Total-Body Irradiation, Thiotepa, Fludarabine - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 45 | 2019-08-29 | 2026-09-25 |
| Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Azacitidine, Cytarabine, Decitabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 76 | 2018-02-02 | 2025-01-16 |
| A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications NKR-2 cells - Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM) | Phase 1 / Phase 2 | Unknown | Celyad Oncology SA | 146 | 2016-12-01 | 2019-09-19 |
| Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Azacitidine, Laboratory Biomarker Analysis, Lenalidomide - Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 282 | 2012-03-01 | 2026-09-09 |
| Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC Cyclophosphamide (CTX, Cytoxan), Fludarabine(Fludara,Berlex Laboratories), Total Body Irradiation (TBI) - MDS, Immunodeficiency | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2009-05-07 | 2020-03-12 |
Leukemia, Myeloid, Acute (3) · Anemia, Refractory, with Excess of Blasts (2) · Leukemia, Myelomonocytic, Chronic (2) · Myelodysplastic Syndromes (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Burkitt Lymphoma (1) · Immunologic Deficiency Syndromes (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Mast-Cell (1) · Leukemia, Myeloid (1) · Multiple Myeloma (1) · Myeloproliferative Disorders (1) · Neutropenia, Severe Congenital, Autosomal Recessive 3 (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Bone Marrow Diseases (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Myelodysplastic Syndromes (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Leukemia (5) · Leukemia, Myeloid (4) · Immune System Diseases (3) · Anemia (2) · Anemia, Refractory (2) · Chronic Disease (2) · Disease Attributes (2)
Azacitidine (2) · Cyclophosphamide (2) · Whole-Body Irradiation (2) · fludarabine phosphate (2) · Antilymphocyte Serum (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Cytarabine (1) · Decitabine (1) · Injections (1) · Lenalidomide (1) · Methotrexate (1) · Nivolumab (1) · Tacrolimus (1) · Thiotepa (1)
National Cancer Institute (NCI) (3) · AB Science (1) · Celyad Oncology SA (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Fred Hutchinson Cancer Center (1) · Servier (1)
United States (6) · Belgium (1) · Canada (1) · France (1) · Greece (1) · Russia (1) · Spain (1)
Dennis D Hickstein, M.D. (1) · Laura C Michaelis (1) · Marie Bleakley (1) · Mikkael A Sekeres (1) · Nicholas Short, MD (1) · Norbert Vey, MD (1)
PMID 21508125, PMID 21816832, PMID 23344397, PMID 24077845, PMID 29133316, PMID 29618479, PMID 33049057, PMID 36764323
U10CA180888 (2), 2025 (1), P01CA018029 (1), P30CA015704 (1), U10CA032102 (1)